Ovagen

Most people who look up Ovagen want liver and gut support, and most of them already know the Khavinson name. These are the short peptides developed at a gerontology institute in St. Petersburg, Russia, where each one is matched to an organ. Ovagen is the one assigned to the liver and digestive tract, which is how the Russian capsule is labeled and how vendors describe the research vial.

The women searching for it tend to be in midlife and already thinking about longevity. Liver health gets more attention after menopause, when fatty liver becomes more common, and Ovagen often shows up as one course in a yearly rotation alongside Pinealon for the brain, Cartalax for cartilage and skin, and Epithalon for overall aging.

When you go looking for the published research on Ovagen's actual sequence, nearly all of it is about the kidneys. The liver use comes from the product line and the vendor pages, not from a liver study of this peptide that we could find. That doesn't make the liver use wrong, it just means the reason people take it and the reason the papers were written are two different stories.

People who take it usually treat it as maintenance rather than a fix. They run a short course once or twice a year, much the way someone might book a dental cleaning, and then leave it alone for months. Nobody we could find describes taking it every day, year round, and nothing in the research sets that up either.

The Khavinson group's idea is that very short peptides can slip into a cell and nudge which genes get switched on, a bit like a sticky note on a recipe telling the cook which steps to repeat. Each peptide in the family is meant to carry a note for one particular organ.

For Ovagen's sequence, the published work goes like this. In aging kidney cells grown in a dish, the same group reported more cell growth and lower levels of the markers cells raise as they wear out. In rats, they gave it before kidney damage from two hard-on-the-kidneys drugs and from a cut-off blood supply, and reported that kidney function held up better than in untreated rats. A later rat study reported better kidney function in older animals.

All of that is cell and rat work, and it comes from one research network. We couldn't find a published study that gave this sequence to a person. A newsletter on Ovagen cites a small Russian clinic report in people with liver trouble, but we couldn't trace it to a published paper, so we're not leaning on it.

The short length is part of why the family interests people. Three amino acids is about as small as a peptide gets, small enough that the group argues it can reach the cell nucleus, where genes live. That idea is plausible and it's been tested in dishes, but the step from a cell culture to a liver in a living woman is the step nobody has measured yet.

In the US, vendors sell Ovagen as a freeze-dried powder, mostly in 20 mg vials, which you mix with bacteriostatic water (sterile water with a preservative, so a vial can be drawn from more than once) and inject under the skin. In Russia it's sold as capsules, each holding 10 mg of the peptide.

The amounts in circulation range widely. Education pages give 100 to 500 mcg a day by injection, a peptide newsletter gives 1 to 2 mg a day for 30 to 60 days, and capsule takers use 10 to 20 mg a day for 10 to 20 days. None of those comes from a human dosing study. The Ovagen dosage page sets each pattern out with its source, the math for a 20 mg vial, and how long a mixed vial lasts.

One practical point shapes the buying. Once water goes into a vial, it keeps for 28 days in the fridge, and at the 100 to 500 mcg a day that education pages give, a 20 mg vial holds far more than a month's worth (the dosage page has the math). People taking the smaller amounts often mix one vial per course and accept that some goes unused, so it pays to plan the course before you order.

Nobody has published a human safety study of Ovagen, so there's no list of side effects measured in people. The rat studies didn't report harm at the amounts they used, and the Russian capsule has been sold as a supplement for years without a public safety warning we could find. That's reassuring as far as it goes, and it doesn't go as far as a trial would.

What people report with injected peptides in this family is mostly a little redness or itch where the needle went in, which usually fades within the hour. People rotate the spot they inject.

A few things deserve extra care. There's no information on pregnancy or breastfeeding. If you have a diagnosed liver or kidney condition, or you take medicines your liver or kidneys handle carefully, that's the situation where a peptide with no human data is hardest to judge. And because a research vial isn't a regulated product, the main day-to-day risk is what's actually in it, which is why we check vendors for independent lab testing and published certificates of analysis.

There's one compound here in two forms. The Russian capsule is taken by mouth and sold as a supplement. The US research vial is powder for injection. The amounts don't carry over between them, since swallowed peptides are partly broken down in the gut, so the capsule amounts run much higher than the injected ones.

Don't confuse Ovagen with Livagen, a separate four-amino-acid peptide from the same group that's also linked to the liver, or with the Ovagen tablet sold in India, which is an unrelated fertility medicine that happens to share the name.

Ovagen isn't approved by the FDA for anything. In the US it's sold as a research compound, labeled for research use, and buying it for that purpose is legal. In Russia the capsule form is sold as a dietary supplement rather than a prescription medicine. It isn't on the World Anti-Doping Agency's named list, though that list bans unapproved substances in general, so tested athletes treat it as off limits.

We haven't written a head-to-head page for Ovagen yet. The compounds people weigh it against are its siblings. Vesugen is the family member assigned to blood vessels, Pinealon the one for the brain, and Cartalax the one for cartilage and skin. For a longevity peptide with a deeper research base, Epithalon is the one most people start with.

When you compare prices, compare the cost per milligram, not the price of the vial, and look for a vendor that publishes independent lab results for the batch you're buying. A certificate of analysis, the lab report that says what's in the vial and how pure it is, matters more for a small, lightly studied peptide like this one, because there's less independent testing across the market to fall back on.

It's sold for research, and the big human trials haven't been run yet. You knew that, it's why you're reading this and not the label.